Alginate oligosaccharides (AlgO), agarose oligosaccharides (AO), and κ-carrageenan oligosaccharides (KCO) were obtained by specific enzymatic hydrolysis method. The molecular weight distributions of the three oligosaccharides were 1.0–5.0 kDa, 0.4–1.4 kDa, and 1.0–7.0 kDa, respectively. The culture medium was supplemented with the three oligosaccharides and fermented by pig fecal microbiota in vitro, for 24 h. Each oligosaccharide was capable of increasing the concentration of short-chain fatty acids (SCFAs), especially butyric acid, and altering the microbiota composition. Linear discriminant analysis effect size (LEfSe) analysis results showed that the opportunistic pathogenic bacteria Escherichia, Shigella, and Peptoniphilus, were significantly decreased in AlgO supplemented medium. AO could improve the gut microbiota composition by enriching the abundance of Ruminococcaceae, Coprococcus, Roseburia, and Faecalibacterium. Besides, KCO could increase the abundance of SCFA microbial producers and opportunistic pathogenic flora. Therefore, these results indicate that AlgO and AO can be used as gut microbial regulators and can potentially improve animal/human gastrointestinal health and prevent gut disease, whereas the physiological function of KCO needs further evaluation.

• Bacterial fucose-containing exopolysaccharides (FcEPSs) are reliable source of fucose. • The bacterial sources, structures, and bioactivities of FcEPSs are reviewed. • FcEPSs provide promising resources for preparing functional carbohydrates.

Food-derived oligosaccharides show promising therapeutic potential in lowering blood pressure (BP), but the mechanism is poorly understood. Recently, the potential role of gut microbiota (GM) in hypertension has been investigated, but the specific GM signature that may participate in hypertension remains unclear. To test the potassium alginate oligosaccharides (PAO) mechanism in lowering BP and specific microbial signature changes in altering GM, we administered various dosages of PAO in 40 spontaneously hypertensive rats for a duration of six weeks. We analyzed BP, sequenced the 16S ribosomal DNA gene in the cecum content, and gathered RNA-seq data in cardiac tissues. We showed that the oral administration of PAO could significantly decrease systolic BP and mean arterial pressure. Transcriptome analyses demonstrated that the protective effects of developing heart failure were accompanied by down-regulating of the Natriuretic Peptide A gene expression and by decreasing the concentrations of angiotensin II and atrial natriuretic peptide in plasma. In comparison to the Vehicle control, PAO could increase the microbial diversity by altering the composition of GM. PAO could also decrease the ratio of Firmicutes to Bacteroidetes by decreasing the abundance of Prevotella and Phascolarctobacterium bacteria. The favorable effect of PAO may be added to the positive influence of the abundance of major metabolites produced by Gram-negative bacteria in GM. We suggest that PAO caused changes in GM, and thus, they played an important role in preventing the development of cardiovascular disease.

The aim of this study was to evaluate the effects of high‐ (HHGG, Mw 10,000–30,000 Da) and medium‐molecular‐weight (MHGG, Mw 2,000–10,000 Da) partially hydrolyzed guar gum (PHGG) on modulation of gut microbiota and relief of constipation in mice. Mice were treated with galacto‐oligosaccharide (GOS) and xylo‐oligosaccharide (XOS) at a dose of 1 g/kg bw as positive controls. Low‐ and high‐dose HHGG and MHGG groups received 250 mg or 1 g/kg bw, respectively. Treatment was administered intragastrically for 15 days, and constipation model was induced by loperamide lavage at d 16. PHGG could increase fecal moisture and small intestinal transit and shortened the time to first black stool defecation after constipation. The highest short‐chain fatty acid production was observed in the high‐dose MHGG group. Additionally, PHGG, GOS, and XOS predominantly promoted the accumulation of Bacteroidetes and inhibited the growth of Desulfovibrio. This study suggested that MHGG treatment could elicit constipation relief in mice. Practical applications In this study, partially hydrolyzed guar gum (PHGG) produced by mannanase hydrolysis was applied for the relieving constipation in mice. The medium‐molecular‐weight product (Mw 2,000–10,000 Da) could elicit constipation relief and modulate the gut microbiota in mice, which shows the potential to act as dietary fiber for constipation treatment.